Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Surfix logo — Redefining Point-of-Care testing

Surfix

Redefining Point-of-Care testing

Founded 2011 The Netherlands The Netherlands 38 employees Biotechnology

General Information

Company Name Surfix
Founded Year 2011
Location The Netherlands The Netherlands +1
Employees 38
Industries Biotechnology
Social

Get notified when Surfix moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Surfix

Surfix Diagnostics, founded in 2011 and headquartered in The Netherlands, is a biotechnology startup with the goal of providing easy-to-use, reliable, and sensitive diagnostic tests for the early detection and monitoring of cancer. The company's photonic diagnostics platform integrates six cutting-edge technologies, enabling the detection of various protein or nucleic acid-based biomarkers in liquid biopsies, provided suitable bioreceptors are available. The core of Surfix's platform is a photonic biosensor, comprising a photonic biochip and a microfluidic cartridge optimized with the company's proprietary nanocoatings. This biosensor, used in conjunction with a dedicated desktop reader, demonstrates versatility as it can be applied to both immunoassays and molecular diagnostics. Despite the absence of publicly available information on last investment and investors, Surfix Diagnostics' innovative approach to cancer diagnostics, underpinned by its advanced photonic diagnostics platform, positions the company as a promising player in the biotechnology industry. With a focus on detecting biomarkers of interest, Surfix is poised to make a significant impact in the early detection and monitoring of cancer, addressing a critical need in healthcare.

Taxonomy: Surfix Diagnostics, Diagnostics, Photonic Diagnostics Platform, Biosensor Technology, Cancer Detection, Early Detection, Liquid Biopsy, Microfluidics, Immunoassays, Molecular Diagnostics, Nanocoatings, Point-of-Care Testing, Biofunctionalization, Lab-on-a-Chip, Bioreceptor

No funding data available for Surfix yet.

Get notified when Surfix raises funding

Surfix Alternatives & Competitors

Surfix vs
vantix® DIAGNOSTICS, Inc
vantix® DIAGNOSTICS, Inc United States

Pioneering precise detection in medical, veterinary, and environmental diagnostics since 2010.

Series Unknown
1 employees
Hardware, Health Care
Surfix vs
AOA Dx
AOA Dx United States

Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI

Unknown
56 employees
Biotechnology, Health Care
Surfix vs
ErleaDx
ErleaDx Singapore

Early Cancer Detection Saves Lives

1 employees
Medical Devices
Also compare with: Surfix vs BillionToOne BillionToOne

FAQ About Surfix

Redefining Point-of-Care testing
Surfix was founded in 2011.
Surfix is headquartered in The Netherlands.
Surfix operates in the following industries: Biotechnology.
Surfix has approximately 38 employees.
Top alternatives and competitors to Surfix include vantix® DIAGNOSTICS, Inc, AOA Dx, ErleaDx , Omini, Digital Diagnostics . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Surfix and vantix® DIAGNOSTICS, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Surfix and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy